Liver dysfunction risk may also be increased when medicinal products that are inhibitors of the bile salt export pump (BSEP), e. g., rifampicin, glibenclamide and cyclosporine A (see sections 4.3 and 4.5), are co- administered with bosentan, but limited data are available.